Merck's KEYTRUDA receives positive CHMP opinions for new administration route and indication
PositiveFinancial Markets

Merck's KEYTRUDA has received positive opinions from the CHMP for a new administration route and indication, marking a significant advancement in cancer treatment options. This development is crucial as it could enhance patient access to this life-saving therapy, potentially improving outcomes for many who rely on it.
— Curated by the World Pulse Now AI Editorial System